Last $3.10 USD
Change Today -0.03 / -0.96%
Volume 22.0K
SPHS On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Frankfurt
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

sophiris bio inc (SPHS) Snapshot

Open
$3.13
Previous Close
$3.13
Day High
$3.15
Day Low
$3.05
52 Week High
01/17/14 - $5.18
52 Week Low
06/23/14 - $2.10
Market Cap
52.2M
Average Volume 10 Days
26.6K
EPS TTM
$-1.72
Shares Outstanding
16.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOPHIRIS BIO INC (SPHS)

Related News

No related news articles were found.

sophiris bio inc (SPHS) Related Businessweek News

No Related Businessweek News Found

sophiris bio inc (SPHS) Details

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of products for the treatment of urological diseases. Its primary product candidate includes PRX302, which is in Phase III clinical trial for treatment for the symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of prostate cancer. Sophiris Bio, Inc. has a strategic relationship with Kissei Pharmaceutical Co., Ltd. or the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. is based in La Jolla, California.

10 Employees
Last Reported Date: 08/7/14

sophiris bio inc (SPHS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $437.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $293.4K
Chief Operating Officer and Head of Research ...
Total Annual Compensation: $339.9K
Compensation as of Fiscal Year 2013.

sophiris bio inc (SPHS) Key Developments

Sophiris Bio Seeks Acquisitions

Sophiris Bio, Inc. (NasdaqGM:SPHS) will consider acquisitions. Sophiris Bio has filed a shelf registration in the amount of $100 million. Sophiris Bio will use the net proceeds for general corporate purposes, which may include research and development, capital expenditures, working capital and general and administrative expenses. It may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although it has no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus.

Sophiris Bio Reports Completion of Enrollment in the 'PLUS-1' Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Sophiris Bio Inc. announced that it has fully enrolled its ongoing Phase 3 trial (referred to as PLUS-1) of PRX302 as a treatment for lower urinary tract symptoms of BPH. The PLUS-1 trial is an international, multi-center, randomized, double-blind and vehicle-controlled Phase 3 study that will assess the safety and efficacy of a single intraprostatic administration of PRX302 (0.6 ug/g prostate) for the treatment of BPH. The primary endpoint is the International Prostate Symptom Score (IPSS) total score change from baseline over 52 weeks. Secondary endpoints include Qmax (maximum urine flow) change from baseline over 52 weeks. BPH is an enlargement of the prostate gland, often resulting in a constricted or partially blocked urethra that can lead to frequent and difficult urination, discomfort, and other complications with urinating. It is estimated that more than five million men in the United States alone are bothered by symptoms of BPH. Current oral drugs for BPH, which are taken daily, often lack sustainable efficacy and may be associated with undesirable side effects including sexual dysfunction. More aggressive treatment options include invasive surgical procedures, which may also cause sexual dysfunction.

Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Sophiris Bio, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss before income taxes of $8,750,000 against $2,642,000 a year ago. Net loss was $8,750,000 or $0.53 per basic and diluted share against $2,642,000 or $0.84 per basic and diluted share a year ago. For the six months, the company reported net loss before income taxes of $17,209,000 against $2,258,000 a year ago. Net loss was $17,209,000 or $1.05 per basic and diluted share against $2,758,000 or $0.88 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPHS:US $3.10 USD -0.03

SPHS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPHS.
View Industry Companies
 

Industry Analysis

SPHS

Industry Average

Valuation SPHS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOPHIRIS BIO INC, please visit www.sophirisbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.